The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Durvalumab as neoadjuvant therapy for muscle-invasive bladder cancer: Preliminary results from the Bladder Cancer Signal Seeking Trial (BLASST)-2.
 
Xiao X. Wei
Honoraria - OncLive
Research Funding - Bristol-Myers Squibb
Travel, Accommodations, Expenses - Corvus Pharmaceuticals
 
Bradley Alexander McGregor
Consulting or Advisory Role - Astellas Pharma; AstraZeneca; Bayer; EMD Serono; Exelixis; Genentech/Roche; Janssen Oncology; Nextar; Pfizer; Seattle Genetics/Astellas
Research Funding - Bristol-Myers Squibb (Inst); Calithera Biosciences (Inst); Exelixis (Inst); Seattle Genetics/Astellas (Inst)
 
Richard J. Lee
Consulting or Advisory Role - Bayer; exelixis; Janssen Oncology; Noxopharm; Tolero Pharmaceuticals
Research Funding - Janssen
 
Xin Gao
No Relationships to Disclose
 
Kerry L. Kilbridge
No Relationships to Disclose
 
Mark A. Preston
No Relationships to Disclose
 
Matthew Mossanen
No Relationships to Disclose
 
Matthew D. Ingham
No Relationships to Disclose
 
Graeme S. Steele
No Relationships to Disclose
 
Alyssa Klein
No Relationships to Disclose
 
Eliezer Mendel Van Allen
Stock and Other Ownership Interests - ervaxx; Genome Medical; Microsoft; Syapse; Tango Therapeutics
Consulting or Advisory Role - ervaxx; Genome Medical; Illumina; InVitae; Novartis; Roche; Syapse; Takeda; Tango Therapeutics; Third Rock Ventures
Speakers' Bureau - Illumina
Research Funding - Bristol-Myers Squibb; Novartis
Patents, Royalties, Other Intellectual Property - Patent on clinical interpretation algorithms using cancer molecular data (Inst); Patent on discovery of chromatin regulators as biomarkers of response to cancer immunotherapy (Inst); Patent on discovery of retained intron as source of cancer neoantigens (Inst)
Travel, Accommodations, Expenses - Roche/Genentech
 
Mariano Severgnini
No Relationships to Disclose
 
Marios Giannakis
Honoraria - AstraZeneca
Research Funding - Bristol-Myers Squibb; Merck
Patents, Royalties, Other Intellectual Property - Patent pending on biomarkers of immune response
 
Guru Sonpavde
Honoraria - UpToDate
Consulting or Advisory Role - Agensys; Astellas Pharma; AstraZeneca; Bayer; Bristol-Myers Squibb; Eisai; EMD Serono; Exelixis; Genentech; Janssen; Merck; Novartis; Sanofi
Speakers' Bureau - Clinical Care Options/NCCN; Onclive; Physicans' Education Resource; Research to Practice
Research Funding - AstraZeneca; Bayer (Inst); Boehringer Ingelheim (Inst); Celgene (Inst); Janssen (Inst); Merck (Inst); Onyx (Inst); Pfizer (Inst); Sanofi (Inst)
Travel, Accommodations, Expenses - Bristol-Myers Squibb
Other Relationship - Astellas Pharma; AstraZeneca; Bavarian Nordic; Boehringer Ingelheim; Bristol-Myers Squibb; Debiopharm Group